当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Angiogenic activity of classical hematopoietic cytokines.

Angiogenic activity of classical hematopoietic cytokines.

Abstract：

:Hematopoiesis is regulated by several cytokines with pleiotropic activity. Several evidences have clearly demonstrated that these molecules, formerly regarded as specific for the hematopoietic system, also affect certain endothelial cell functions and that hematopoietic factors clearly influence angiogenesis. This review article summarizes the most important literature data concerning this inconvertible relationship.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Ribatti D

doi

10.1016/j.leukres.2012.02.003

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

537-43

issue

5

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(12)00049-5

journal_volume

36

pub_type

杂志文章,评审

相关文献

LEUKEMIA RESEARCH文献大全
  • Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.

    abstract：:Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (IL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. IL-4 at 0.01 ng/ml protected from spontaneous ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(96)00053-7

    authors： Frankfurt OS,Byrnes JJ,Villa L

    更新日期：1997-01-01 00:00:00

  • Analysis of T-cell receptor-γ gene rearrangements using heteroduplex analysis by high-resolution microcapillary electrophoresis.

    abstract：:Determination of T-cell clonality has an important additional value for diagnosis of T-cell lymphomas. Various molecular methods have been developed, including polymerase chain reaction (PCR) of T-cell receptor γ (TCRγ). The detection of PCR products usually relies commonly on either GeneScan (GS) analysis or heterodu...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.06.003

    authors： Beaufils N,Ben Lassoued A,Essaydi A,Dales JP,Formisano-Tréziny C,Bonnet N,Grob JJ,Gabert J

    更新日期：2012-09-01 00:00:00

  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

    abstract：:Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2013.01.004

    authors： Adès L,Sekeres MA,Wolfromm A,Teichman ML,Tiu RV,Itzykson R,Maciejewski JP,Dreyfus F,List AF,Fenaux P,Komrokji RS

    更新日期：2013-06-01 00:00:00

  • BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

    abstract：:We compared the efficacy and toxicity of BEAM (BCNU, etoposide, cytarabine and melphalan) and BuCyE (busulfan, cyclophosphamide and etoposide), given prior to autologous stem cell transplantation (ASCT), in 65 patients with non-Hodgkin's lymphoma. Of these 65 patients, 43 received BEAM and 22 received BuCyE. Their age...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2010.07.016

    authors： Kim JE,Lee DH,Yoo C,Kim S,Kim SW,Lee JS,Park CJ,Huh J,Suh C

    更新日期：2011-02-01 00:00:00

  • Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells.

    abstract：:Zerumbone (ZER) is a potential anticancer natural compound, isolated from Zingiber zerumbet Smith. In this investigation, the anticancer properties of ZER were evaluated on cancer cells of T-acute lymphoblastic leukemia, CEM-ss. The results showed that ZER has cytotoxic effect against CEM-ss cells with an IC(50) of 8....

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.07.025

    authors： Abdelwahab SI,Abdul AB,Mohan S,Taha MM,Syam S,Ibrahim MY,Mariod AA

    更新日期：2011-02-01 00:00:00

  • A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.

    abstract：:We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma. BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.03.026

    authors： Burmeister T,Macleod RA,Reinhardt R,Mansmann V,Loddenkemper C,Marinets O,Drexler HG,Thiel E,Blau IW

    更新日期：2006-11-01 00:00:00

  • Isoenzyme studies in human leukemia-lymphoma cell lines--V. Induction of differentiation by T-cell derived differentiation-inducing activity.

    abstract：:A panel of human leukemia cell lines from various lineages (T-cell, pre B- and Non-T/Non-B cell, myelomonocytic and erythroleukemia cell lines) were utilised as model systems of the distant effects of differentiation-inducing activity (DIA) produced by the T-leukemia cell line HUT-102. DIA inhibited cell proliferation...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90108-1

    authors： Drexler HG,Notani J,Otsuka K,Gaedicke G,Minowada J

    更新日期：1987-01-01 00:00:00

  • Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172.

    abstract：:Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2019.106225

    authors： Liu M,Liao H,Chen Y,Lin Z,Liu Y,Zhang X,Chan HC,Sun H

    更新日期：2019-11-01 00:00:00

  • The venom of the spider Macrothele raveni induces apoptosis in the myelogenous leukemia K562 cell line.

    abstract：:Spider venoms are a rich source of bioactive compounds with therapeutic potential. In traditional Chinese medicine, spiders and spider venoms have been used in the treatment of various ailments. In the present study, the venom of the spider Macrothele raveni potently suppressed cell growth in the myelogenous leukemia ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.02.025

    authors： Liu Z,Zhao Y,Li J,Xu S,Liu C,Zhu Y,Liang S

    更新日期：2012-08-01 00:00:00

  • Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

    abstract：:Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regime...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(01)00114-x

    authors： Murohashi I,Kashimura T,Tominaga K,Wakao D,Takahashi T,Akiba M,Kishimoto K,Yoshida K,Yagasaki F,Itoh Y,Sakata T,Kawai N,Itoh K,Suzuki T,Matsuda A,Hirashima K,Bessho M

    更新日期：2002-03-01 00:00:00

  • Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.

    abstract：:Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) patients and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 patients to the 89 cases from the...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2010.07.031

    authors： Noor SJ,Tan W,Wilding GE,Ford LA,Barcos M,Sait SN,Block AW,Thompson JE,Wang ES,Wetzler M

    更新日期：2011-05-01 00:00:00

  • Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.

    abstract：:Although recent advances in chemotherapy have markedly improved outcome of acute lymphoblastic leukemia (ALL), infantile ALL with MLL gene rearrangements (MLL+ALL) is refractory to chemotherapy. We have shown that specific cytokines FLT3 ligand and TGFβ1 both of which are produced from bone marrow stromal cells synerg...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.11.001

    authors： Ando N,Furuichi Y,Kasai S,Tamai M,Harama D,Kagami K,Abe M,Goi K,Inukai T,Sugita K

    更新日期：2018-12-01 00:00:00

  • Potentiation of glucocorticoid-induced cytolysis in sensitive human leukemic cells by an inhibitor of ADP-ribosylation.

    abstract：:3-Aminobenzamide, a general inhibitor of poly(ADP-ribose)polymerase, potentiated the triamcinolone acetonide-mediated growth inhibition and lysis of the glucocorticoid-sensitive CEM-C7 human leukemic cell line. This potentiation was dose-dependent with maximal response being detected at 3 mM 3-aminobenzamide, and was ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90181-8

    authors： Meyer AS,Schlechte JA,Schmidt TJ

    更新日期：1990-01-01 00:00:00

  • Kappa light chain gene rearrangement in a T-cell lymphoma.

    abstract：:Forty-three patients were studied to determine whether light chain gene rearrangements may occur in hematopoietic cells not pertaining to the B-lineage. In only one patient, affected by T-cell lymphoblastic lymphoma, one kappa light chain allele was rearranged. Neither at the protein level nor at the RNA level the rea...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90145-j

    authors： Moretti L,Mariano MT,Donelli A,Montagnani G,Sarti M,Grantini M,Di Prisco U,Torelli U,Narni F

    更新日期：1991-01-01 00:00:00

  • Incidence of haematological malignancies in French Polynesia between 1990 and 1995.

    abstract：:To determine the incidence of haematological malignancies in French Polynesia from 1990 to 1995, we collected cases from the local cancer registry, sanitary evacuation files and all the histopathology and clinical biology laboratories. All leukaemias, non Hodgkin's lymphomas, and multiple myelomas incidence was slight...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00186-6

    authors： Roda L,de Vathaire F,Rio B,Le Tourneau A,Petididier P,Laudon F,Zittoun R

    更新日期：1999-04-01 00:00:00

  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.

    abstract：:Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2005.10.025

    authors： Moore J,Seiter K,Kolitz J,Stock W,Giles F,Kalaycio M,Zenk D,Marcucci G

    更新日期：2006-07-01 00:00:00

  • Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.

    abstract：:To improve the recovery rate of high-risk patients with acute promyelocytic leukemia (APL), we used all-trans retinoic acid (ATRA)/arsenic trioxide (ATO)/daunorubicin combination in remission induction, daunorubicin and cytarabine in consolidation, and ATRA/ATO/methotrexate ± 6-mercaptopurine in maintenance treatment ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.03.027

    authors： Huang H,Qin Y,Xu R,You X,Teng R,Yang L,Xu M,Liu H

    更新日期：2012-07-01 00:00:00

  • Elevated argininosuccinate synthetase activity in adult T leukemia cell lines.

    abstract：:Argininosuccinate synthetase (ASS) is a ATP-dependent and rate-limiting enzyme of the urea cycle which catalyzes L-citrulline to L-arginine in combination with argininosuccinate lyase (ASL). We demonstrate here that (a) human normal T and B lymphocytes did not express ASS activity, (b) however, three adult T leukemia ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90184-b

    authors： Sugimura K,Kimura T,Arakawa H,Ohno T,Wada Y,Kimura Y,Saheki T,Azuma I

    更新日期：1990-01-01 00:00:00

  • PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.

    abstract：:Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.09.025

    authors： Nuutinen U,Simelius N,Ropponen A,Eeva J,Mättö M,Eray M,Pellinen R,Wahlfors J,Pelkonen J

    更新日期：2009-06-01 00:00:00

  • Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.

    abstract：:The oral bacterium, Aggregatibacter actinomycetemcomitans, produces a leukotoxin (LtxA) that is specific for white blood cells (WBCs) from humans and Old World primates by interacting with lymphocyte function antigen-1 (LFA-1) on susceptible cells. To determine if LtxA could be used as a therapeutic agent for the trea...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.08.022

    authors： Kachlany SC,Schwartz AB,Balashova NV,Hioe CE,Tuen M,Le A,Kaur M,Mei Y,Rao J

    更新日期：2010-06-01 00:00:00

  • Pathogenesis of jumping translocations: a molecular cytogenetics study.

    abstract：BACKGROUND/AIMS:Jumping translocations are rare cytogenetic aberrations in haematological malignancies, the pathogenesis of which remains to be fully characterised. We investigated the mechanism of formation of jumping translocations in a case of adult common acute lymphoblastic leukaemia (ALL) positive for the Ph tran...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.01.021

    authors： Wan TS,Ma SK,Chow EY,Li YH,Lin SY,Chan LC

    更新日期：2004-10-01 00:00:00

  • Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia.

    abstract：:Fluorescent-labeled DNA probes were used to study 52 chronic lymphocytic leukemia (B-CLL) patients for (1) disease progression, (2) angiogenesis genes, (3) T-cell leukemia 1 gene (TCL1), (4) immunoglobulin heavy chain variable region (IGHv) and (5) chromosome 6q. Compared to stable disease, more patients with progress...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.07.012

    authors： Fink SR,Paternoster SF,Smoley SA,Flynn HC,Geyer SM,Shanafelt TD,Lee YK,Jelinek DF,Kay NE,Dewald GW

    更新日期：2005-03-01 00:00:00

  • The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

    abstract：BACKGROUND:The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs). DESIGN AND METHODS:We conducted a dose-escalating study of daunorubicin combined to fixed doses of IM (imatinib mesylate, 600 mg/d) an...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.leukres.2010.11.004

    authors： Deau B,Nicolini FE,Guilhot J,Huguet F,Guerci A,Legros L,Pautas C,Berthou C,Guyotat D,Cony-Makhoul P,Gardembas M,Michallet M,Hayette S,Cayuela JM,Weiss IR,Réa D,Castaigne S,Mahon FX,Guilhot F,Rousselot P

    更新日期：2011-06-01 00:00:00

  • Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.

    abstract：:This study uses single cell network profiling (SCNP) to characterize biological pathways associated with in vitro resistance or sensitivity to chemotherapeutics commonly used in acute myeloid leukemia (AML) (i.e. cytarabine/daunorubicin, gemtuzumab ozogamicin (GO), decitabine, azacitidine, clofarabine). Simultaneous m...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.02.022

    authors： Rosen DB,Cordeiro JA,Cohen A,Lacayo N,Hogge D,Hawtin RE,Cesano A

    更新日期：2012-07-01 00:00:00

  • Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

    abstract：:Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the las...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.012

    authors： Zhu HH,Jiang H,Jiang Q,Jia JS,Qin YZ,Huang XJ

    更新日期：2016-05-01 00:00:00

  • A monoclonal antibody (SJ-9A4) to P24 present on common alls, neuroblastomas and platelets - I. Characterization and development of a unique radioimmunometric assay.

    abstract：:We report the development and characterization of SJ-9A4, a monoclonal antibody (MoAb) produced against common acute lymphoblastic leukemia (C-ALL) cell lines. SJ-9A4 reacted with C-ALL, B-cell chronic lymphocytic leukemia (B-CLL), platelets and C-ALL neuroblastoma (NB) and the K562 cell lines. It had no significant r...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(83)90044-9

    authors： Komada Y,Peiper SC,Melvin SL,Metzger DW,Tarnowski BH,Green AA

    更新日期：1983-01-01 00:00:00

  • A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naïve T cells.

    abstract：:We established a plasmacytoid dendritic cell (pDC) line (PMDC05) from leukemia cells of pDC leukemia. PMDC05 cells were positive for CD4, CD56, CD33, HLA-DR, CD123 (IL-3Ralpha) and CD86 in the absence of lineage markers. mRNA of TLR1, TLR2, TLR4, TLR7 and TLR9 was clearly expressed and among these TLRs, TLR7 was promi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.047

    authors： Narita M,Watanabe N,Yamahira A,Hashimoto S,Tochiki N,Saitoh A,Kaji M,Nakamura T,Furukawa T,Toba K,Fuse I,Aizawa Y,Takahashi M

    更新日期：2009-09-01 00:00:00

  • Reversing the multidrug resistance in acute leukemia: until the leukemia initiating cell?

    abstract：:Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38- phenot...

    journal_title：Leukemia research

    pub_type： 评论,社论

    doi：10.1016/j.leukres.2008.09.022

    authors： Costello RT

    更新日期：2009-06-01 00:00:00

  • Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

    abstract：:Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-pla...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.10.004

    authors： Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

    更新日期：2009-06-01 00:00:00

  • The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

    abstract：:AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve patients (six AML; six MDS) were treated with AG-013736 at a dose of 10...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.10.024

    authors： Giles FJ,Bellamy WT,Estrov Z,O'Brien SM,Verstovsek S,Ravandi F,Beran M,Bycott P,Pithavala Y,Steinfeldt H,Reich SD,List AF,Yee KW

    更新日期：2006-07-01 00:00:00